Tandem Diabetes Care Inc. (NASDAQ:TNDM) shares saw an uptick in trading volume on Thursday . 216,895 shares changed hands during mid-day trading, a decline of 15% from the previous session’s volume of 253,856 shares.The stock last traded at $7.84 and had previously closed at $7.94.

A number of brokerages have commented on TNDM. Robert W. Baird reaffirmed a “buy” rating on shares of Tandem Diabetes Care in a report on Monday, May 2nd. Piper Jaffray Cos. reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Tandem Diabetes Care in a report on Thursday, April 21st. Bank of America Corp. lowered Tandem Diabetes Care from a “neutral” rating to an “underperform” rating in a report on Thursday, March 24th. Zacks Investment Research raised Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $9.25 price objective on the stock in a report on Wednesday, May 4th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $20.00 price objective on shares of Tandem Diabetes Care in a report on Wednesday, June 15th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. Tandem Diabetes Care presently has a consensus rating of “Buy” and an average target price of $14.21.

The stock has a 50 day moving average of $7.36 and a 200-day moving average of $8.44. The company’s market cap is $237.34 million.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its quarterly earnings results on Thursday, April 28th. The medical device company reported ($0.68) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.69) by $0.01. The business had revenue of $20.06 million for the quarter, compared to the consensus estimate of $17.67 million. The business’s revenue was up 63.0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.83) earnings per share. On average, equities research analysts anticipate that Tandem Diabetes Care Inc. will post ($2.16) earnings per share for the current year.

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.